CHIATAI TIANQING

CHIATAI TIANQING is an innovative pharmaceutical group engaged in pharmaceutical innovation and the research, production, and sales of high-quality medicines. It is committed to providing patients with better health solutions and affordable, high-quality medical resources. As a well-known domestic R&D and production base for anti-tumor and liver disease drugs in China, CHIATAI TIANQING is a national key high-tech enterprise and a key backbone enterprise of the National Torch Program Lianyungang New Pharmaceutical Industry Base. The company ranked 16th on the 2019 list of Top 100 Pharmaceutical Industrial Enterprises in China and was named the Best Industrial Enterprise in China for Pharmaceutical R&D Product Lines in 2020 (evaluated and published by the China Pharmaceutical Industry Information Center). CHIATAI TIANQING always regards scientific and technological innovation as the supporting force for sustainable corporate development. It is one of the pharmaceutical companies in China that invests heavily in innovative drug research, with annual R&D investment accounting for 10-12% of sales revenue. CHIATAI TIANQING uses its Research Institute as an innovation carrier and has successively established high-level R&D platforms such as the "Jiangsu Province New Liver Disease Drug Engineering Technology Research Center," "Postdoctoral Research Station," "National Enterprise Technology Center," and "Jiangsu Province Antiviral Targeted Drug Research Key Laboratory." Its independent innovation capabilities continue to strengthen. Currently, the company has 196 projects under development, including 82 innovative drugs, 74 chemical generic drugs, and 40 biopharmaceuticals. It holds more than 500 valid domestic invention patents and over 200 valid overseas invention patents, forming a healthy pattern of "one generation on the market, one generation in reserve, and one generation in development."